Literature DB >> 10102710

Pivotal role of nitric oxide in the control of blood pressure after leptin administration.

G Frühbeck1.   

Abstract

Leptin administration has been shown to increase renal, adrenal, and lumbar sympathetic nerve activity. However, this generalized sympathoexcitatory activity is not always followed by an increase in arterial pressure. The present study tested the hypothesis that leptin induces a release of nitric oxide (NO) that opposes the pressor effect of sympathoexcitation. The effect of intravenous administration of leptin (10, 100, and 1,000 microg/kg body wt) or vehicle on blood pressure (BP), heart rate (HR), and serum nitrite/nitrate concentrations of anesthetized Wistar rats was examined. At 90 min after injection, the three leptin doses tested increased serum NO concentrations 20.5, 33.1, and 89.5%, respectively (P < 0.001 vs. baseline). The effect of leptin on NO concentrations was significantly dose-dependent on linear trend testing (P = 0.0001). In contrast, leptin did not change serum nitrite/nitrate concentrations of fa/fa rats. Leptin administration to Wistar rats under NO synthesis inhibition (N(omega)-nitro-L-arginine methyl ester [L-NAME]) produced a statistically significant increase (P < 0.05) in both systolic BP and mean arterial pressure as well as in HR (P < 0.01). Injection of leptin into rats with pharmacologically induced ganglionic blockade (chlorisondamine) was followed by a decrease in BP and HR to values significantly lower (P < 0.01) than those observed with chlorisondamine treatment alone. The leptin-induced hypotension observed in the setting of ganglionic blockade was blocked by L-NAME. These findings raise the possibility that the leptin-induced release of NO may contribute to the homeostasis of BP.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10102710     DOI: 10.2337/diabetes.48.4.903

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  70 in total

Review 1.  New developments in mechanisms of obesity-induced hypertension: role of adipose tissue.

Authors:  A M Sharma; S Engeli; T Pischon
Journal:  Curr Hypertens Rep       Date:  2001-04       Impact factor: 5.369

2.  Adipose tissue as regulator of vascular tone.

Authors:  Charlotte Boydens; Nele Maenhaut; Bart Pauwels; Kelly Decaluwé; Johan Van de Voorde
Journal:  Curr Hypertens Rep       Date:  2012-06       Impact factor: 5.369

Review 3.  Selective leptin resistance revisited.

Authors:  Allyn L Mark
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-07-24       Impact factor: 3.619

4.  Cardiovascular Consequences of Obesity and Targets for Treatment.

Authors:  Bettina Mittendorfer; Linda R Peterson
Journal:  Drug Discov Today Ther Strateg       Date:  2008

5.  Effects of leptin on cardiovascular physiology.

Authors:  Johnathan D Tune; Robert V Considine
Journal:  J Am Soc Hypertens       Date:  2007 Jul-Aug

Review 6.  Control of respiratory and cardiovascular functions by leptin.

Authors:  M Bassi; W I Furuya; D B Zoccal; J V Menani; E Colombari; J E Hall; A A da Silva; J M do Carmo; D S A Colombari
Journal:  Life Sci       Date:  2015-01-30       Impact factor: 5.037

Review 7.  Do cardiac and perivascular adipose tissue play a role in atherosclerosis?

Authors:  Gianluca Iacobellis; Yu-Jing Gao; Arya M Sharma
Journal:  Curr Diab Rep       Date:  2008-02       Impact factor: 4.810

8.  Promotion of melanoma growth by the metabolic hormone leptin.

Authors:  Julie A Ellerhorst; A H Diwan; Shyam M Dang; Deon G Uffort; Marilyn K Johnson; Carolyn P Cooke; Elizabeth A Grimm
Journal:  Oncol Rep       Date:  2010-04       Impact factor: 3.906

Review 9.  Impaired cardiac function in leptin-deficient mice.

Authors:  Jun Ren; Heng Ma
Journal:  Curr Hypertens Rep       Date:  2008-12       Impact factor: 5.369

Review 10.  Leptin: sympathetic and cardiovascular effects.

Authors:  Robert J Richards; Anthony Blalock; Jie Liao; Efrain Reisin
Journal:  Curr Cardiol Rep       Date:  2003-11       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.